Bastiaan R. Bloem

Terry Yi Zhong, Cristian Tejedor-Garcia, Khiet P. Truong et al.

Early-stage Parkinson's disease (EarlyPD) detection from speech is clinically meaningful yet underexplored, and published results are hard to compare because studies differ in datasets, languages, tasks, evaluation protocols, and EarlyPD definitions. To address this issue, we propose the first benchmark for speech-based EarlyPD detection, with a speaker-independent split designed for fair and replicable cross-method evaluation on researcher-accessible datasets. The benchmark covers three common speech tasks and evaluates methods under different training-resource settings. We also present multi-dimensional evaluation breakdowns by dataset, aggregation level, gender, and disease stage to support fine-grained comparisons and clinical adoption. Our results provide a replicable reference and actionable insights, encouraging the adoption of this publicly available benchmark to advance robust and clinically meaningful EarlyPD detection from speech.

Terry Yi Zhong, Cristian Tejedor-Garcia, Martha Larson et al.

Parkinson's Disease (PD) affects over 10 million people globally, with speech impairments often preceding motor symptoms by years, making speech a valuable modality for early, non-invasive detection. While recent deep-learning models achieve high accuracy, they typically lack the explainability required for clinical use. To address this, we propose RECA-PD, a novel, robust, and explainable cross-attention architecture that combines interpretable speech features with self-supervised representations. RECA-PD matches state-of-the-art performance in Speech-based PD detection while providing explanations that are more consistent and more clinically meaningful. Additionally, we demonstrate that performance degradation in certain speech tasks (e.g., monologue) can be mitigated by segmenting long recordings. Our findings indicate that performance and explainability are not necessarily mutually exclusive. Future work will enhance the usability of explanations for non-experts and explore severity estimation to increase the real-world clinical relevance.

Tahereh Zarrat Ehsan, Michael Tangermann, Yağmur Güçlütürk et al.

Accurately quantifying motor characteristics in Parkinson disease (PD) is crucial for monitoring disease progression and optimizing treatment strategies. The finger-tapping test is a standard motor assessment. Clinicians visually evaluate a patient's tapping performance and assign an overall severity score based on tapping amplitude, speed, and irregularity. However, this subjective evaluation is prone to inter- and intra-rater variability, and does not offer insights into individual motor characteristics captured during this test. This paper introduces a granular computer vision-based method for quantifying PD motor characteristics from video recordings. Four sets of clinically relevant features are proposed to characterize hypokinesia, bradykinesia, sequence effect, and hesitation-halts. We evaluate our approach on video recordings and clinical evaluations of 74 PD patients from the Personalized Parkinson Project. Principal component analysis with varimax rotation shows that the video-based features corresponded to the four deficits. Additionally, video-based analysis has allowed us to identify further granular distinctions within sequence effect and hesitation-halts deficits. In the following, we have used these features to train machine learning classifiers to estimate the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) finger-tapping score. Compared to state-of-the-art approaches, our method achieves a higher accuracy in MDS-UPDRS score prediction, while still providing an interpretable quantification of individual finger-tapping motor characteristics. In summary, the proposed framework provides a practical solution for the objective assessment of PD motor characteristics, that can potentially be applied in both clinical and remote settings. Future work is needed to assess its responsiveness to symptomatic treatment and disease progression.